Studies have shown increased FGF21 in obesity and NAFLD [48, 49], whereas pharmacological administration of FGF21 is beneficial to body weight loss, alleviation of fatty liver, dyslipidemia and hyperglycemia [50–52]. The gene discussed is FGF21; the disease is Hepatic steatosis.